Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia
Expects to add two U.S. Food and Drug Administration (“FDA”)-approved, new chemical entities (“NCEs”) with patent life into 2031 and expand acute care footprintCommercialized assets, BARHEMSYS® (amisulpride for injection) and ...
